Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision was largely random, as neither works equally well for everyone. Now, new research has identified a genetic marker that can predict which medication will be most effective for each patient before therapy begins.

An international team led by the University of Münster (Münster, Germany) discovered that carriers of the HLA-A 03:01 tissue type respond significantly better to glatiramer acetate than to interferon beta. Their study analyzed more than 3,000 MS patients in a multicenter trial, with results published in eBioMedicine. This genetic information offers a clear, evidence-based criterion for personalized treatment selection.

Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Researchers examined T-cell receptor sequences in blood samples from 3,021 patients across several international cohorts. Specific T-cell clones were found after glatiramer acetate therapy only in patients with HLA-A*03:01 or HLA-DRB1*15:01. However, a proven clinical benefit—fewer symptoms and improved outcomes—was observed only in carriers of the HLA-A*03:01 allele, affecting about 30–35% of European MS patients.

The results were validated in five independent cohorts from the USA, France, and Germany, including the NationMS cohort. In all analyses, HLA-A*03:01 carriers on glatiramer acetate showed significantly better outcomes than those treated with interferon beta. This robust and reproducible finding confirms the biomarker’s clinical utility.

Because human leukocyte antigen (HLA) testing is already widely used in transplant medicine and drug safety, the discovery can be implemented in clinical consultations in the short term. Beyond guiding treatment decisions, the study also provides new insight into glatiramer acetate’s mechanism of action, suggesting that only a few protein fragments may drive its therapeutic effects. This could lead to optimized drug formulations in the future.

"Our study shows for the first time that a genetic marker is linked to the treatment success of an MS medication. This allows us to predict before starting therapy whether glatiramer acetate or interferon is likely to be the better choice," said Professor Nicholas Schwab, study leader.

Related Links:
University of Münster